地址：武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话：17754422825
传真：18771149750
邮箱：sales@amyjet.com
艾美捷科技特约代理BioPorto Diagnostics A/S公司产品。
BioPorto Diagnostics A/S公司成立于2001年，是丹麦一家专门生产抗体和基于抗体的各种生物产品的公司。BioPorto拥有Bioporto Diagnostics和Antibodyshop两个品牌，分别侧重于诊断试剂盒和抗体产品。在30多个国家有代理商，产品销售网络遍布全球，99%以上为出口销售。BioPorto Diagnostics旗下产品主要为几种临床快速诊断试剂盒，包括诊断早期急性肾损伤的NGAL ELISA kit，Gc-globulin ELISA kit ，评估原发性免疫缺陷的MBL Oligomer ELISA kit，同时还有相关其他种属的科研用试剂盒和抗原抗体。其最新推出的产品有检测人体血浆中的活性蛋白C-蛋白C抑制物(APC-PCI)复合物的APC-PCI ELISA kit，高纯度人IgE单克隆抗体，以及Glucagon-like peptide-1和Exendin-4相关的单抗。
BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Our pioneering product portfolio includes assays for underserved disease states such as NGAL for acute kidney injury. We sell our products in more than 80 countries through diverse sales channels and partners. BioPorto has its headquarters in Copenhagen, Denmark and is listed on the Nasdaq Copenhagen stock exchange.
< " data-original="http://aves.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Bioporto"> Bioporto
Swant专注于钙结合蛋白相关产品的研发和销售，产品包括：钙结合蛋白抗体、纯化的重组蛋白、钙离子通道和钙泵抗体以及其他抗体和ELISA。
Antibodies to Calbindin D-28k, Calretinin, Parvalbumin, Calmodulin and to Na2+-Ca2+-exchangers, Ca2+ pumps, neurotransmitters, as well as their respective antigens. Superb staining of subpopulation of neurons or glial cells in various species, including humans. Selective staining of various types of cancers. Our mono- and polyclonal antibodies are of high titer and of high specificity. They can be used in immunohistochemistry and immunoblots at dilution of more than 1:5'000 (Avidin-Biotin-Method). The recombinant antigens have been purified by HPLC and FPLC. The products are supplied in lyophilized form and are accompanied by detailed product description as well as by a method sheet.
Swant 的主要产品包括：
（1）Antibodies against Ca2+ - binding proteins
Calbindin
Calretinin
Parvalbumin
Others
（2）Purified and recombinant proteins
Calbindin
Calretinin
Parvalbumin
Others
（3）Antibodies against Ca2+ exchangers and Ca2+ pumps
Ca2+ - exchangers
Ca2+ - pumps
（4）Various
Antibodies against insulin-like growth factors
Antibodies against neurotransmitters
Antibodies against components of the renin-angiotensin system
Miscellaneous antibodies
（5）ELISA KITS
Sandwich-ELISA
<更多详情请联系
艾美捷科技有限公司
全国服务热线：400-6800-868
邮箱：sales@amyjet.com
网站：www.amyjet.com
< " data-original="http://aves.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Swant"> Swant
Sterlitech是世界上最大的实验室无机膜产品生产公司之一。其产品包括纯银膜、PCTE膜、PETE膜等产品，以及HP4750等膜过滤设备。在很多著名的化学实验室、生物实验室有广泛应用。
美国Stetlitech公司是世界上最大的实验室用无机膜生产商之一。出品纯银金属膜（Silver Metal Filter Membranes）；醋酸纤维素滤膜（Cellulose Acetate membrane filters）；陶瓷膜（ceramic membrane）；玻璃纤维滤膜（glass fiber filters），硝化纤维素滤膜（Nitrocellulose Mixed Esters）；尼龙膜（Nylon membrane）；聚碳酸酯径迹蚀刻膜（Polycarbonate Track Etch （PCTE） membrane）；聚醚砜膜（PES（Polyethersulfone） membrane），聚酯膜（Polyester PETE membrane）；聚丙烯滤膜（polypropylene membrane filters）；特氟隆膜（PTFE Teflon ®））。
更多详情请联系
艾美捷科技有限公司
全国服务热线：400-6800-868
邮箱：sales@amyjet.com
网站：www.amyjet.com
" data-original="http://aves.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Sterlitech"> Sterlitech
SERO生产以下系列专利产品Seronorm™, Pathonorm™ and Autonorm™。除此之外，也为客户提供个性化定制产品。
Seronorm™系列
主要产品包括免疫对照，结合激素，心脏和肿瘤标志物，Seronorm™所有对照血清来源为人，不含防腐剂和稳定剂，产品文档全面，为市场上最常用的仪器提供超过50种分析物的分配值，可提供四个不同临床级别，且每一级别都可单独提供。Seronorm™ Immunoassay Liq low – 含有与临床相当的低水平的醛固酮，雄烯二酮，皮质醇，铁蛋白，IgE，17-OH-孕酮，PSA总量，睾酮，游离T4，TSH，25-OH-维生素D和维生素B12
Pathonorm™ and Autonorm™
Pathonorm™临床化学级对照，不含防腐剂和稳定剂的动物血清，适合大部分临床化学分析，为市面上常用仪器提供超过38种分析物的分配值，有两种临床级别，且都可以单独提供，产品以冻干粉形式提供，货架期长。
Autonorm™
满足绝大部分临床化学实验室正常水平的分析级的高品质对照，不含防腐剂和稳定剂的动物血清，不含Pharmaca。文档齐全，为市场上最常用的仪器提供超过30种分析物的分配值，冻干粉，货架期长。
客户定制产品：
SERO也针对有质量意识的诊断公司，组织提供定制服务，SERO可定制的高品质对照产品如下：
常规血清化学（人或动物基质）
常规尿液化学
脂质
激素
肿瘤标记
心脏标志物
蛋白质
治疗药物
专业和护理点控制（CRP，HbA1C，血红蛋白，葡萄糖）
微量元素和重金属
<更多详情请联系
艾美捷科技有限公司
全国服务热线：400-6800-868
邮箱：sales@amyjet.com
网站：www.amyjet.com
" data-original="http://aves.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="SERO"> SERO
艾美捷科技代理Steraloids Inc. 全系列产品。
Steraloids致力于为研究者提供2700种不同的类固醇雄激素，雌激素，孕激素，cholestins、胆汁酸、激素和代谢产物。
Steroids for Research: 2700 different androgens, estrogens, cholestins, progestins, bile-acids, hormones, and metabolites. Synthetic of endogenous, synthesized to purified standards.
<<| 产品列表 | ||
| 产品名称 | 产品编号 | CAS# |
| 1,(5α)-ANDROSTEN-4-AZA-3-ONE-17β-(N-TERT-BUTYL-CARBOXAMIDE) | A4370-000 | CAS 98319-26-7 |
| 1, (5α)-ANDROSTEN-3, 17-DIONE | A4400-000 | CAS 571-40-4 |
| 1(5α)-ANDROSTEN-1β-METHYL-17β-OL-3-ONE | A4420-000 | CAS 153-00-4 |
| 1(5α)-ANDROSTEN-1β-METHYL-17β-OL-3-ONE ACETATE | A4421-000 | CAS No |
| 1,(5α)-ANDROSTEN-1β-METHYL-17β-OL-3-ONE ENANTHATE | A4444-000 | CAS 303-42-4 |
| 1,(5α)-ANDROSTEN-2- METHYL-17β- OL-3-ONE | A4448-200 | CAS 5197-58-0 |
| 2(5α)-ANDROSTEN-17α-METHYL, 17β-OL | A4900-000 | CAS 3275-64-7 |
| 2, (5α)-ANDROSTEN-17β-OL | A4960-000 | CAS 2639-53-4 |
| 2, (5α)-ANDROSTEN-17β-OL ACETATE | A4961-000 | CAS No |
| 4-ANDROSTEN-3α, 17α-DIOL | A5480-000 | CAS 15183-38-7 |
| 4-ANDROSTEN-3α, 17α-DIOL DIACETATE | A5490-000 | CAS No |
| 4-ANDROSTEN-3α, 17β-DIOL | A5500-000 | CAS 1852-61-5 |
| 4-ANDROSTEN-4-OL-3, 17-DIONE METHYL ETHER | A6507-000 | CAS No |
| 4-ANDROSTEN-6α-OL-3, 17-DIONE | A6520-000 | CAS 24704-84-5 |
| 5-ANDROSTEN-17β-ACETAMIDO-3β-OL ACETATE | A7320-000 | CAS No |
| 5-ANDROSTEN-17β-AMINO-3β-OL | A7400-000 | CAS 4350-66-7 |
| 5-ANDROSTEN-16α-BROMO-3β-OL-17-ONE | A7500-000 | CAS No |
| 5α-ANDROSTAN-17α-METHYL-17β-OL-3-ONE | A2080-000 | CAS 521-11-9 |
| 5α-ANDROSTAN-17α-METHYL-17β-OL-3-ONE ACETATE | A2081-000 | CAS No |
| 5α-ANDROSTAN-17α-METHYL-17β-OL-3-ONE 3-0-CARBOXYMETHYLOXIME | A2085-000 | CAS No |
| 5α-ANDROSTAN-17α-METHYL-17β-OL-3-ONE HEMISUCCINATE | A2090-000 | CAS No |
| 5β-ANDROSTAN-17β-OL-3-ONE | A3730-000 | CAS 571-22-2 |
| 5β-ANDROSTAN-17β-OL-3-ONE ACETATE | A3731-000 | CAS No |
| 5β-ANDROSTAN-17β-OL-3-ONE BENZOATE | A3733-000 | CAS No |
| A-NOR-5α-ANDROSTAN-2α, 17α-DIETHYNYL-2β, 17β-DIOL DIPROPIONATE | N0100-000 | CAS 56470-64-5 |
| 9(11), (5α)-ANDROSTEN-3, 17-DIONE | A8950-000 | CAS 15375-19-6 |
| 9(11), (5β)-ANDROSTEN-3α-OL-17-ONE | A9000-000 | CAS 571-49-3 |
| 9(11),(5β)-ANDROSTEN-3β,17α-DIOL | A8940-000 | CAS No |
| 16, (5α)-ANDROSTEN-3-ONE-3-CMO | A9258-000 | CAS No |
| 16, (5α)-ANDROSTEN-3-ONE-3-CARBOXYMETHYLOXIME : BSA | A9260-000 | CAS No |
| 16, (5α)-ANDROSTEN-3-ONE-3-CMO : HORSERADISHPEROXIDASE | A9264-000 | CAS No |
| 5, 15,-ANDROSTADIEN-3β-0L-17-ONE | A0602-000 | CAS 17921-64-1 |
| 1, 4-ANDROSTADIENE-3, 17-DIONE | A0100-000 | CAS 897-06-3 |
| 1, 4-ANDROSTADIEN-3, 17-DIONE 17-ETHYLENEKETAL | A0110-000 | CAS 2398-63-2 |
| 3, 5-ANDROSTADIEN-17β-OL | A0353-000 | CAS 2602-86-0 |
| 3, 5-ANDROSTADIEN-3-OL-17-ONE 3-ETHYL ETHER | A0380-000 | CAS 972-46-3 |
| 4, 6-ANDROSTADIEN-17α-METHYL-17β-OL-3-ONE | A0402-000 | CAS No |
| 5, 16-ANDROSTADIEN-17-CYANO-3β-OL | A0630-000 | CAS No |
| 1, 4-ANDROSTADIEN-17β-OL-3-ONE GLUCURONIDE | A0207-200 | CAS No |
| 1, 4-ANDROSTADIEN-17α-METHYL-17β-OL-3-ONE | A0130-040 | CAS 72-63-9 |
| 1, 4-ANDROSTADIEN-17α-METHYL-6β, 17β-DIOL-3-ONE-6-ACETATE | A0125-080 | CAS No |
| 5, 16-ANDROSTADIEN-3β-OL-17β-CARBOXYLIC ACID 3-ACETATE | A0681-000 | CAS No |
| 5, 16-ANDROSTADIEN-3β-OL-17β-CARBOXYLIC ACID ETHYL ESTER | A0685-000 | CAS No |
| 5, 16-ANDROSTADIEN-3β-OL-17β-CARBOXYLIC ACID METHYL ESTER | A0689-000 | CAS No |
| 5, 16-ANDROSTADIEN-3-ONE-17β-CARBOXYLIC ACID | A0695-000 | CAS No |
| 1, 4-ANDROSTADIEN-17α-OL-3-ONE | A0190-000 | CAS No |
| 1, 4-ANDROSTADIEN-6β,17β-DIOL-3-ONE | A0085-000 | CAS No |
| 4, 16-ANDROSTADIEN-3α-OL | A0555-000 | CAS 6306-63-0 |
| 1, 4-ANDROSTADIEN-17β-OL-3-ONE-2,4,6,6-d4 | A0200-040 | CAS 846-48-0 |
| 1, 4, 6-ANDROSTATRIEN-17β-OL-3-ONE ACETATE | A4201-000 | CAS No |
| 1, 4, 7-ANDROSTATRIEN-17β-OL-3-ONE | A4250-000 | CAS No |
| 4-CHOLESTEN-3β-OL ACETATE | C6101-000 | CAS No |
| 4-CHOLESTEN-3β-OL BENZOATE | C6103-000 | CAS No |
| 4-CHOLESTEN-2α-OL-3-ONE | C6180-000 | CAS No |
| 5-CHOLESTEN-3β, 25-DIOL 3-HEMISUCCINATE | C6520-000 | CAS No |
| 5-CHOLESTEN-3β, 25-DIOL 3-OLEATE | C6525-000 | CAS No |
| 5-CHOLESTEN-3, 25-DIOL, 25-SULPHATE, SODIUM SALT | C6538-000 | CAS No |
| 5-CHOLESTEN-3β, 25-DIOL-7-ONE | C6550-000 | CAS No |
| 5-CHOLESTEN-3β, 25-DIOL-7-ONE ACETATE | C6551-000 | CAS No |
| 5-, 25R-CHOLESTEN-3β, 26-DIOL | C6570-000 | CAS 20380-11-4 |
| 5-CHOLESTEN-24(S), 25-EPOXY-3β-OL | C6640-000 | CAS 77058-74-3 |
| 5-CHOLESTEN-24β-ETHYL-3β-OL ~78% | C6680-000 | CAS 83-46-5 |
| 5-CHOLESTEN-24β-ETHYL-3β-OL -25,26,26,26,27,27,27 -D7 | C6680-015 | CAS 83-46-5 |
| 5-CHOLESTEN-24β-ETHYL-3β-OL ~54% | C6680-050 | CAS 83-46-5 |
| 5-CHOLESTEN-24β-ETHYL-3β-OL ~78% | C6680-080 | CAS 000083-46-5 |
| 5-CHOLESTEN-24β-ETHYL-3β-OL ACETATE | C6681-000 | CAS 000915-05-9 |
| 5-CHOLESTEN-24α-ETHYL-3β-OL CHLOROFORMATE | C6683-000 | CAS No |
| 5-CHOLESTEN-24-ETHYL-3-OL-7-ONE | C6684-000 | CAS 2034-74-4 |
| 5-CHOLESTEN-24(28)-ETHYLIDENE-3β-OL | C6685-000 | CAS 17605-67-3 |
| 5-CHOLESTEN-25-FLUORO-3βOL | C6688-000 | CAS No |
| 5-CHOLESTEN-24α-METHYL 3β-OL | C6700-000 | CAS 474-62-4 |
| 5-CHOLESTEN-24α-METHYL 3β-OL-30% 24β | C6700-010 | CAS 474-62-4 |
| 5-CHOLESTEN-24α-METHYL 3β-OL-BENZOATE | C6703-000 | CAS No |
| 5-CHOLESTEN-6-NITRO-3β-OL ACETATE | C6711-000 | CAS No |
| 5-CHOLESTEN-6-NITRO-3β-OL BENZOATE | C6713-000 | CAS No |
| 5-CHOLESTEN-3α-OL | C6730-000 | CAS No |
| 5-CHOLESTEN-3α-OL ACETATE | C6731-000 | CAS No |
| 5-CHOLESTEN-3β-OL | C6760-000 | CAS 57-88-5 |
| 5-CHOLESTEN-3β-OL-25,26,26,26,27,27,27-D7 | C6760-020 | CAS 57-88-5 |
| 5-CHOLESTEN-3β-OL ACETATE | C6761-000 | CAS 604-35-3 |
| 5-CHOLESTEN-3β-OL ACETOACETATE | C6762-000 | CAS No |
| 5-CHOLESTEN-3β-OL N-BUTYRATE | C6775-000 | CAS 521-13-1 |
| 5-CHOLESTEN-3β-OL BENZOATE | C6770-000 | CAS 604-32-0 |
| 5-CHOLESTEN-3-OL CAPROATE | C6780-000 | CAS No |
| 5-CHOLESTEN-3β-OL CAPRYLATE | C6785-000 | CAS No |
| 5-CHOLESTEN-3β-OL-(25R)CARBOXYLIC ACID | C6786-000 | CAS No |
| 5-CHOLESTEN-3β-OL-(25S)CARBOXYLIC ACID | C6787-000 | CAS No |
| 5-CHOLESTEN-3β-OL CHLOROACETATE | C6790-000 | CAS 3464-50-4 |
| 5-CHOLESTEN-3β-OL CHLOROFORMATE | C6795-000 | CAS 7144-08-3 |
| 5-CHOLESTEN-3β-OL CINNAMATE | C6800-000 | CAS 1990-11-0 |
| 5-CHOLESTEN-3β-OL N-DECYLATE | C6805-000 | CAS 1183-04-6 |
| 5-CHOLESTEN-3-OL DOCOSAHEXAENOATE(4,7,10,13,16,19) | C6807-000 | CAS No |
| 5-CHOLESTEN-3β-OL ETHYL ETHER | C6812-000 | CAS 98-61-96 |
| 5-CHOLESTEN-3β-OL FORMATE | C6815-000 | CAS 4351-55-7 |
| 5-CHOLESTEN-3β-OL GLUCOSIDURONATE, SODIUM SALT | C6821-000 | CAS No |
| 5-CHOLESTEN-3β-OL HEMISUCCINATE | C6823-000 | CAS 1510-21-0 |
| 5-CHOLESTEN-3β-OL N-HEPTYLATE | C6825-000 | CAS 1182-07-6 |
| 5-CHOLESTEN-3β-OL ISO-BUTYRATE | C6840-000 | CASNoCH Groups C31 H52 |
| 5-CHOLESTEN-3β-OL LAURATE | C6845-000 | CAS 190-8-11-8 |
| 5-CHOLESTEN-3β-OL METHYLCARBONATE | C6855-000 | CAS 15507-52-5 |
| 5-CHOLESTEN-3β-OL METHYL ETHER | C6860-000 | CAS 1174-92-1 |
| 5-CHOLESTEN-3β-OL MYRISTATE | C6865-000 | CAS 1989-52-2 |
| 5-CHOLESTEN-3β-OL OLEATE | C6870-000 | CAS 303-43-5 |
| 5-CHOLESTEN-3β-OL OLEYL ETHER | C6871-000 | CAS No |
| 5-CHOLESTEN-3β-OL PALMITATE | C6875-000 | CAS No |
| 5-CHOLESTEN-3β-OL PELARGONATE | C6880-000 | CAS 1182-66-7 |
| 5-CHOLESTEN-3-OL PHENYLPROPIONATE | C6890-000 | CAS 14914-99-9 |
| 5-CHOLESTEN-3β-OL PROPIONATE | C6895-000 | CAS 633-31-8 |
| 5-CHOLESTEN-3β-OL PYRIDINIUM SULPHATE | C6903-000 | CAS No |
| 5-CHOLESTEN-3β-OL STEARATE | C6904-000 | CAS 35602-69-8 |
| 5-CHOLESTEN-3β-OL SULPHATE, SODIUM SALT | C6905-000 | CAS 2864-50-8 |
| 5-CHOLESTEN-3β-OL P-TOLUENESULPHONATE | C6910-000 | CAS 1182-65-6 |
| 5-CHOLESTEN-3β-OL SULPHATE TRIETHYL AMMONIUM SALT | C6911-000 | CAS No |
| 5-CHOLESTEN-3β-OL N-VALERATE | C6915-000 | CAS 1182-07-6 |
| 5-CHOLESTEN-3β-OL-7-ONE | C6970-000 | CAS 566-28-9 |
| 5-CHOLESTEN-3β-OL-7-ONE ACETATE | C6971-000 | CAS No |
| 5-CHOLESTEN-3β-OL-7-ONE BENZOATE | C6973-000 | CAS No |
| 5-CHOLESTEN-3-OL-7-ONE-7-CARBOXYMETHYLOXIME | C6980-000 | CAS 566-28-9 |
| 5-CHOLESTEN-3-OL-22-ONE | C7020-000 | CAS 19243-30-2 |
| 5-CHOLESTEN-3-OL-22-ONE ACETATE | C7021-000 | CAS No |
| 5-CHOLESTEN-3β- OL-24-ONE | C7030-000 | CAS 17752-16-8 |
| 5-CHOLESTEN-3-ONE | C7050-000 | CAS 601-54-7 |
| 5-CHOLESTEN-7-ONE | C7060-000 | CAS No |
| 5-CHOLESTEN-3, 7α, 25-TRIOL | C7085-000 | CAS No |
| 5-CHOLESTEN-3β, 16β, 26(25R)-TRIOL | C7090-000 | CAS No |
| 5-CHOLESTEN-3, 17α, 20α-TRIOL | C7100-000 | CAS No |
| N-ACETYL-5-METHOXYTRYPTAMINE-α,α,β,β-D4 | Z0600-000 | CAS 73-31-4 |
| 5-CHOLESTEN-3β, 4α-DIOL | C6400-000 | CAS 34310-86-6 |
更多详情请联系
艾美捷科技有限公司
全国服务热线：400-6800-868
邮箱：sales@amyjet.com
网站：www.amyjet.com
" data-original="http://aves.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Steraloids"> SteraloidsLDN公司是德国专业的免疫检测试剂生产厂家。LDN成立于1996年，已经成长为全球领先的生物胺免疫分析产品的公司，拥有超过35名员工。目前，LDN在60多个国家提供200多种产品。客户来自临床实验室、研究机构、制药公司和食品行业。
<主要产品和服务：
| 产品领域 | 检测物 | 产品名称 | 货号 | 规格 |
| Research | Serotonin | Serotonin Research ELISA | BA E-5900 | 96T |
| Research | Catecholamines | Adrenaline Research ELISA | BA E-5100 | 96T |
| Research | Catecholamines | Noradrenaline Research ELISA | BA E-5200 | 96T |
| Research | Catecholamines | Dopamine Research ELISA | BA E-5300 | 96T |
| Research | Catecholamines | 2-CAT (A-N) Research ELISA | BA E-5400 | 96T |
| Research | Catecholamines | 2-CAT (N-D) Research ELISA | BA E-5500 | 96T |
| Research | Catecholamines | 3-CAT Research ELISA | BA E-5600 | 96T |
| Research | Histamine | Histamine Research ELISA TM | BA E-5800 | 96T |
| Research | Tryptophan | Tryptophan ELISA | BA E-2700 | 96T |
| Research | GABA | GABA ELISA | BA E-2500 | 96T |
| Research | Glycine | Glycine ELISA | BA E-2100 | 96T |
| Research | Kynurenine | Kynurenine ELISA | BA E-2200 | 96T |
| Research | Citrulline | Citrulline ELISA | BA E-2800 | 96T |
| Research | ANIMAL RESEARCH | Testosterone Rat/Mouse ELISA | AR E-8000 | 96T |
| Research | ANIMAL RESEARCH | Corticosterone Rat/Mouse ELISA | AR E-8100 | 96T |
| Research | ANIMAL RESEARCH | Prolactin Rat ELISA | AR E-8200 | 96T |
| Research | ANIMAL RESEARCH | Estrone-3-Sulfate Equine ELISA | AR E-8300 | 96T |
| Research | ANIMAL RESEARCH | Prolactin Canine ELISA | AR E-8400 | 96T |
| Research | ANIMAL RESEARCH | TSH Canine ELISA | AR E-8500 | 96T |
| Research | ANIMAL RESEARCH | TSH Rat ELISA | AR E-8600 | 96T |
| Research | ANIMAL RESEARCH | Progesterone Mouse/Rat | AR E-8700 | 96T |
| Research | ANIMAL RESEARCH | Estradiol Rat | AR E-8800 | 96T |
| Food Safety | HistaSure™ ELISA High Sensitive | FC E-3100 | 96T | |
| Food Safety | HistaSure™ ELISA Fast Track (48 determinations) | FC E-3600 | 96T | |
| Food Safety | HistaSure™ XL ELISA Fast Track (480 determinations) | FC E-3900 | 96T | |
| Food Safety | HistaSure™ Fish Rapid Test | FC L-3200 | 96T | |
| Endocrinology | Androgen Assessment | Androstenedione ELISA | AA E-1000 | 96T |
| Endocrinology | Androgen Assessment | DHEA-S ELISA | AA E-1100 | 96T |
| Endocrinology | Androgen Assessment | SHBG ELISA | AA E-1200 | 96T |
| Endocrinology | Androgen Assessment | Testosterone ELISA | AA E-1300 | 96T |
| Endocrinology | Androgen Assessment | Androstanediol-Glucuronide ELISA | AA E-1500 | 96T |
| Endocrinology | Androgen Assessment | DHEA ELISA | AA E-1600 | 96T |
| Endocrinology | Androgen Assessment | DHT ELISA | AA E-1700 | 96T |
| Endocrinology | Androgen Assessment | Free Testosterone ELISA 2nd Generation | AA E-1800 | 96T |
| Endocrinology | Fertility & Reproduction | Estradiol ELISA | FR E-2000 | 96T |
| Endocrinology | Fertility & Reproduction | Free Estriol ELISA | FR E-2100 | 96T |
| Endocrinology | Fertility & Reproduction | Estrone ELISA | FR E-2300 | 96T |
| Endocrinology | Fertility & Reproduction | Progesterone ELISA | FR E-2500 | 96T |
| Endocrinology | Fertility & Reproduction | Pregnenolone ELISA | FR E-2700 | 96T |
| Endocrinology | Fertility & Reproduction | 17-OH-Progesterone ELISA | FR E-2800 | 96T |
| Endocrinology | Metabolism | C-Peptide ELISA | ME E-0100 | 96T |
| Endocrinology | Metabolism | hGH ELISA | ME E-0200 | 96T |
| Endocrinology | Metabolism | Leptin ELISA | ME E-0300 | 96T |
| Endocrinology | Metabolism | IGFBP-1 ELISA | ME E-0400 | 96T |
| Endocrinology | Metabolism | IGF-1 ELISA | ME E-0500 | 96T |
| Endocrinology | Metabolism | Insulin ELISA | ME E-0900 | 96T |
| Endocrinology | Mineral/Salt balance | Cortisol ELISA | MS E-5000 | 96T |
| Endocrinology | Mineral/Salt balance | Cortisol Urine ELISA | MS E-5100 | 96T |
| Endocrinology | Mineral/Salt balance | Aldosterone ELISA | MS E-5200 | 96T |
| Endocrinology | Mineral/Salt balance | Active Renin ELISA | MS E-5300 | 96T |
| Endocrinology | Mineral/Salt balance | Corticosterone ELISA | MS E-5400 | 96T |
| Endocrinology | Mineral/Salt balance | Plasma Renin Activity ELISA (PRA) | MS E-5600 | 96T |
| Endocrinology | Mineral/Salt balance | 25-OH-Vitamin D (total) ELISA | MS E-5800 | 96T |
| Endocrinology | Thyroid Function | TSH ELISA 2nd Generation | TF E-2000 | 96T |
| Endocrinology | Thyroid Function | fT3 ELISA 2nd Generation | TF E-2100 | 96T |
| Endocrinology | Thyroid Function | fT4 ELISA 2nd Generation | TF E-2200 | 96T |
| Endocrinology | Thyroid Function | T3 ELISA 2nd Generation | TF E-2300 | 96T |
| Endocrinology | Thyroid Function | T4 ELISA 2nd Generation | TF E-2400 | 96T |
| Endocrinology | Thyroid Function | Reverse T3 (rT3) ELISA | TF E-2500 | 96T |
| Endocrinology | Tumor Markers | CEA ELISA | TM E-4100 | 96T |
| Endocrinology | Tumor Markers | CA 125 ELISA | TM E-4300 | 96T |
| Endocrinology | Tumor Markers | CA 15-3 ELISA | TM E-4400 | 96T |
| Endocrinology | Tumor Markers | CA 19-9 ELISA | TM E-4500 | 96T |
| Endocrinology | Tumor Markers | β2-Microglobulin ELISA | TM E-4600 | 96T |
| Endocrinology | Tumor Markers | hNSE ELISA | TM E-4700 | 96T |
| Endocrinology | Tumor Markers | Chromogranin A ELISA | TM E-9000 | 96T |
| Endocrinology | Disease Markers | CRPHigh Sensitive ELISA | DM E-4600 | 96T |
| Endocrinology | Saliva Assays | Cortisol Saliva ELISA | SA E-6000 | 96T |
| Endocrinology | Saliva Assays | Testosterone Saliva ELISA | SA E-6100 | 96T |
| Endocrinology | Saliva Assays | Estradiol Saliva ELISA | SA E-6200 | 96T |
| Endocrinology | Saliva Assays | Progesterone Saliva ELISA | SA E-6300 | 96T |
| Endocrinology | Saliva Assays | 17-OH-Progesterone Saliva ELISA | SA E-6400 | 96T |
| Endocrinology | Saliva Assays | DHEA-S Saliva ELISA | SA E-6500 | 96T |
| Endocrinology | Saliva Assays | Free Estriol Saliva ELISA | SA E-6600 | 96T |
| Endocrinology | Saliva Assays | Androstenedione Saliva ELISA | SA E-6700 | 96T |
| Endocrinology | Saliva Assays | IgA Saliva ELISA | SA E-6800 | 96T |
| Endocrinology | Saliva Assays | Alpha-Amylase Saliva ELISA | SA E-6900 | 96T |
| Endocrinology | Saliva Assays | DHEA Saliva ELISA | SA E-7000 | 96T |
| Endocrinology | Saliva Assays | Estrone Saliva ELISA | SA E-7100 | 96T |
| Endocrinology | Saliva Assays | SALI – SET | CATALOG | 96T |
| Endocrinology | Saliva Assays | SALI – SET 100 | SA D-6100 | 96T |
| Endocrinology | Saliva Assays | SALI – SET 500 | SA D-6500 | 96T |
| Endocrinology | Animal Research | Testosterone Rat/Mouse ELISA | AR E-8000 | 96T |
| Endocrinology | Animal Research | Corticosterone Rat/Mouse ELISA | AR E-8100 | 96T |
| Endocrinology | Animal Research | Prolactin Rat ELISA | AR E-8200 | 96T |
| Endocrinology | Animal Research | Estrone-3-Sulfate Equine ELISA | AR E-8300 | 96T |
| Endocrinology | Animal Research | Prolactin Canine ELISA | AR E-8400 | 96T |
| Endocrinology | Animal Research | TSH Canine ELISA | AR E-8500 | 96T |
| Endocrinology | Animal Research | TSH Rat ELISA | AR E-8600 | 96T |
| Endocrinology | Animal Research | Progesterone Mouse/Rat | AR E-8700 | 96T |
| Endocrinology | Animal Research | Estradiol Rat | AR E-8800 | 96T |
| Glycine in urine | Glycine in urine | Glycine ELISA | BA E-2100 | 96T |
更多详情请联系
艾美捷科技有限公司
全国服务热线：400-6800-868
邮箱：sales@amyjet.com
网站：www.amyjet.com
< " data-original="http://aves.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="LDN公司全系列ELISA Kits"> LDN公司全系列ELISA Kits
艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年，提供近200种亚磷酰胺和核苷酸合成用固相交联单体，以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.
Berry & Associates的主要产品包括：
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://aves.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸
ViroStat于1985年，由Douglas McAllister博士创立，致力于为研究者和工业界提供传染性疾病的抗体产品。产品线涵盖病毒学、细菌学和寄生虫学，应用于呼吸道药、性病药、胃肠药/毒素和食源性致病菌的检测。ViroStat拥有超过500种传染性疾病相关的试剂，其中包括MONOTOPE系列单克隆抗体、PMNITOPE多克隆抗体和数量众多的重组蛋白抗原。基于长期的经验积累，ViroStat能够提供从100ug到10g级别的产品。
ViroStat was founded in 1985 by Dr. Douglas McAllister to provide infectious disease antibody tools to researchers and manufacturers. These include the areas of virology, bacteriology and parasitology. Applications for these include detection of respiratory agents, STD agents, gastrointestinal agents/toxins and food borne pathogens.
The company offers more than 500 infectious disease reagents including their MONOTOPE™ monoclonal antibodies, OMNITOPE™ polyclonal antibodies and numerous recombinant antigens. Many of these antibodies are used by manufacturers of rapid, point of care tests currently made and sold in the US.
ViroStat公司产品包括：
MONOTOPE™ - Monoclonal Antibodies (Mouse) 小鼠单克隆抗体
RABMAB® - Monoclonal Antibodies (Rabbit) 兔单克隆抗体
OMNITOPE™ - Polyclonal Antibodies多克隆抗体
RECOMBINANT ANTIGENS 重组抗原
<更多详情请联系
艾美捷科技有限公司
全国服务热线：400-6800-868
邮箱：sales@amyjet.com
网站：www.amyjet.com
" data-original="http://aves.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="ViroStat"> ViroStat
<艾美捷科技代理GenoSensor Corporation品牌全系列产品
GenoSensor Corporation是一家基因组技术公司，专注于为从事基因组研究和/或需要基因组解决方案的生命科学领域客户提供产品和服务。公司产品线包括：微RNA芯片、PCR/实时定量PCR（QPCR）试剂盒、基因组改变分析工具，DNA提取试剂盒以及临床应用的专用试剂盒及试剂。
▎GenoSensor Corporation产品线
● MicroRNA Expression Profiling
MicroRNA是约21个核苷酸（NT）的非编码小RNA，参与转录后调控，并在多种细胞和生物体中表达。GenoExplorer™ microRNA生物芯片和检测方法为研究microRNA表达及其谱分析提供了支持。microRNA芯片包括人、小鼠、大鼠、果蝇、秀丽隐杆线虫、拟南芥以及其他物种的芯片，GenoExplorer™微阵列以高重复性、高信噪比和高灵敏度为标志，展现出高品质性能。
| 货号 | 品名 | 产品描述 | 规格 |
| 1101C | GenoExplorer™ microRNA kit - human 4 | GenoExplorer™ microRNA chips, labeling reagent, hybridization buffer and washing solutions | 4 reactions |
| 1102C | GenoExplorer™ microRNA kit - human 20 | 20 reactions | |
| 1111C | GenoExplorer™ microRNA kit - mouse/rat 4 | 4 reactions | |
| 1112C | GenoExplorer™ microRNA kit - mouse/rat 20 | 20 reactions | |
| 1121C | GenoExplorer™ microRNA kit - C. elegans 4 | 4 reactions | |
| 1122C | GenoExplorer™ microRNA kit - C. elegans 20 | 20 reactions | |
| 1131C | GenoExplorer™ microRNA kit - Drosophila melanogaster 4 | 4 reactions | |
| 1132C | GenoExplorer™ microRNA kit - Drosophila melanogaster 20 | 20 reactions | |
| 1141C | GenoExplorer™ microRNA kit - Arabidopsis thaliana 4 | 4 reactions | |
| 1142C | GenoExplorer™ microRNA kit - Arabidopsis thaliana 20 | 20 reactions | |
| 1199 | GenoExplorer™ microRNA for other species | - | |
| 1301 | GenoExplorer™ microRNA array labeling kit | GenoExplorer™microRNA labeling kit | 20 reactions |
| 1302 | GenoExplorer™microRNA labeling kit is ONLY available with purchase of full kits | GenoExplorer™microRNA labeling kit is ONLY available with purchase of full kits | 4 reactions |
| 1201C | GenoExplorer™ microRNA cihp - human 4 | GenoExplorer™ microRNA chips and 2x hybridization buffer | 4 chips (4 arrays) |
| 1202C | GenoExplorer™ microRNA cihp - human 20 | 20 chips (20 arrays) | |
| 1211C | GenoExplorer™ microRNA cihp - mouse/rat 4 | 4 chips (4 arrays) | |
| 1212C | GenoExplorer™ microRNA chip - mouse/rat 20 | 20 chips (20 arrays) | |
| 1221C | GenoExplorer™ microRNA chip - C. elegans 4 | 4 chips (4 arrays) | |
| 1222C | GenoExplorer™ microRNA chip - C. elegans 20 | 20 chips (20 arrays) | |
| 1231C | GenoExplorer™ microRNA chip - Drosophila melanogaster 4 | 4 chips (4 arrays) | |
| 1232C | GenoExplorer™ microRNA chip - Drosophila melanogaster 20 | 20 chips (20 arrays) | |
| 1241C | GenoExplorer™ microRNA chip - Arabidopsis thaliana 4 | 4 chips (4 arrays) | |
| 1242C | GenoExplorer™ microRNA chip - Arabidopsis thaliana 20 | 20 chips (20 arrays) | |
| 1299 | GenoExplorer™ microRNA for other species | - | |
| 1401C | GenoExplorer™ microRNA probe set - human | 1 complete GenoExplorer™ microRNA probe set for human in 384-well plates | 500 pmol |
| 1411C | GenoExplorer™ microRNA probe set - mouse/rat | 1 complete GenoExplorer™ microRNA probe set for mouse in 384-well plates | 500 pmol |
| 1421C | GenoExplorer™ microRNA probe set - C. elegans | 1 complete GenoExplorer™ microRNA probe set for C. elegans in a 384-well plate | 500 pmol |
| 1431C | GenoExplorer™ microRNA probe set - Drosophila melanogaster | 1 complete GenoExplorer™ microRNA probe set for Drosophila melanogaster in a 384-well plate | 500 pmol |
| 1441C | GenoExplorer™ microRNA probe set - Arabidopsis thaliana | 1 complete GenoExplorer™ microRNA probe set for Arabidopsis thaliana in a 384-well plate | 500 pmol |
| 1499 | GenoExplorer™ microRNA for other species | 1 complete GenoExplorer™ microRNA probe set in 384-well plates | - |
| 1501 | 2x Hybridization buffer | 2x hybridization buffer with optimized salt and formamide | 5 x 1ml |
| 1502 | 2x printing buffer | 2x phosphate printing buffer pH 8.3 | 100 ml |
| 1503 | Blocking buffer | Blocking buffer (or Buffer S for GenoExplorer array kit) | 5 x 1ml |
| 1504 | Washing buffers | Washing buffer I and II (concentrated) | 120 and 50 ml |
● MicroRNA qRT-PCR Analysis
GenoExplorer™microRNA qRT-PCR试剂盒提供了一个简单且高灵敏度的工具，用于定量检测特定的miRNA。该试剂盒可测量miRNA的成熟形式或前体形式，或者同时测量两种形式。
<| 货号 | 品名 | 产品描述 | 规格 |
| 2001 | GenoExplorer™ miRNA qRT-PCR Kit-100 | Provides complete set for miRNA quantitation including first-strand cDNA synthesis and SYBR® Green I qPCR reagent mix. (primers not included, see Cat# 2003 and 2004) | 100 reactions |
| 2002-10 | GenoExplorer™ miRNA First-Strand cDNA Core Kit-10 | Provides necessary core components to generate miRNA first-strand cDNA for miRNA expression quantitation. | 10 reactions |
| 2002-50 | GenoExplorer™ miRNA First-Strand cDNA Core Kit-50 | 50 reactions | |
| 2003 | GenoExplorer™ miRNA qPCR Primer Sets | Provides specific primer pair for miRNA quantitation analysis (3µM each). Suggest to combine with GenoExplorer™ miRNA qRT-PCR Kit-100 (Cat# 2001) and reference primer sets (Cat# 2004). Refer miRBase for available genes and primers. | 100 µl |
| 2004 | GenoExplorer™ miRNA qPCR Reference Primer Sets | Reference primer as an internal control reference (3µM each). Suggest to combine with GenoExplorer™ miRNA qRT-PCR Kit-100 (Cat# 2001) and GenoExplorer™ miRNA qPCR Primer Sets (Cat# 2003).Selection of human-U6, human-U44, human-5SrRNA; mouse-U6, mouse-5SrRNA; rat-U6, rat-5SrRNA; Drosophila-U6 and 5SrRNA | 100 µl |
| 2005 | GenoExplorer™ 2X qPCR Mix | 2X SYBR® Green I qPCR mix, specifically for miRNA and small RNA amplification and quantification, containing all PCR reagents and polymerase | 750 µl |
● Gene Expression Profiling
GenoExplorer™ 基因表达谱分析生物芯片包括：针对选定基因及其可变剪接异构体的定制微阵列，涵盖人、小鼠、大鼠及其他物种的完整基因文库，以及用于表达研究的基因子集。
| 品名 | 产品描述 |
| GenoExplorer™ Human Genome Chips | Microarray contains 29K human microRNA sequences |
| GenoExplorer™ Human Functional Genomics Chips | Microarrays include the subsets of functional genes and ESTs, such as signal transduction, liver enzymes, etc. |
| Custom Chips | We will help you design your custom chips for the genes that you are interested in. |
● COVID-19检测试剂盒
GenoSensor开发了一种高灵敏度检测方法，利用实时逆转录聚合酶链反应（RT-PCR） 直接检测病毒基因组（RNA），具有操作简便和可实时检测得特点。
| 货号 | 品名 | 产品描述 | 规格 |
| 2702-22 | GS™ COVID-19 Real-Time PCR Kit - 30 | Provide all-in-one master mix including cDNA synthesis, PCR mix, primers and probe of each gene. | 22 samples |
| 2702-94 | GS™ COVID-19 Real-Time PCR Kit - 126 | 94 samples |
● QS™ DNA 提取试剂盒
QS™ DNA 提取试剂盒包含的试剂能够裂解细胞、使蛋白质变性，并保护核酸免受核酸酶和氧化作用的降解。该方法极其快速且简单，只需两步操作，即可从多种类型的组织和细胞中提取 DNA，提取的可直接用于 PCR 和测序分析，无需纯化步骤。
| 货号 | 品名 | 产品描述 | 规格 |
| QS8001 | QS™ DNA Extraction kit | Solution A (Lysis)100ml and Solution B (Balance) | 10ml |
▎GenoSensor Corporation提供的服务
● 基因组改变分析：包括多态性基因分型（如SNPs和STRs）、基因组结构分析、基因扩增与缺失分析以及基因组重排分析。
● 定制微阵列：根据提供探针化学物质，构建经过质量控制的阵列。临床应用：专门为癌症和心血管疾病开发和销售基因产品。
● 靶标制备：例如从组织、培养物和微生物中分离和纯化基因组DNA、质粒DNA和RNA。
● 靶基因扩增、定量和标记：提供基因扩增、产物定量和靶标标记服务。
● 测序：基因测序使用ABI测序系统进行。
艾美捷科技特约代理Avidity Biosciences公司产品。
Avidity Biosciences公司位于美国加州La Jolla，是一家专门从事抗体寡核苷酸结合物（AOC™）技术开发的生物技术公司，此项技术结合了单抗组织选择性和寡核苷酸疗法的精确性，克服了寡核苷酸给药屏障。
Avidity Biosciences is a privately-held biotech company pioneering Antibody Oligonucleotide Conjugates (AOC™). AOCs combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapeutics to overcome barriers to the delivery of oligonucleotides and target genetic drivers of disease.
Antibody oligonucleotide conjugate (AOC™) technology
Avidity’s antibody oligonucleotide conjugate (AOC™) technology utilizes antibodies to target cells and tissues of interest and facilitate the uptake and internalization of oligonucleotide payloads. By combining the cellular and tissue selectivity of antibodies with the selectivity and efficiency of oligo-based approaches, Avidity has demonstrated modulation of disease-related RNAs in diverse cell types and tissues including muscle, heart, liver, tumors and immune cells.
" data-original="http://aves.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Avidity Biosciences"> Avidity Biosciences地址：武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话：18771997407
传真：18771149750
邮箱：sales@amyjet.com
0.3186
